What is Antibe Therapeutics Inc. (ATBPF)?

Antibe Therapeutics Inc. (ATBPF) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of ATBPF?

The current price of ATBPF is $0.22. Prices are updated in real time on Stocks360.

What is ATBPF's price-to-earnings (PE) ratio?

ATBPF's trailing twelve-month PE ratio is -0.81, based on current price and earnings per share data available on Stocks360.

What is ATBPF's market capitalization?

ATBPF's market capitalization is $11,428,827.00, placing it in the small-cap tier.

Antibe Therapeutics Inc. (ATBPF)

Stock analysis · OTC · Healthcare · Medical - Devices

$0.22

Market Cap

$11.43M

PE (TTM)

-0.81

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.58

Day Range

$0.19 – $0.22

52-wk Range

$0.19 – $0.22

Avg Volume

N/A

Volume

17.93K

Antibe Therapeutics Inc. (ATBPF) is a publicly traded company in the Healthcare sector. Latest price: $0.22. Market cap $11.43M. Trailing PE -0.81. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Feb 14, 2024

EPS $-0.06 vs est. $-0.09

Beat by $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.81×
P/S (TTM)	0.00×
P/B	0.39×
P/FCF (TTM)	-0.98×
EV / EBITDA	-0.48×
EV / Sales	0.00×
Earnings Yield	-123.77%
Free Cash Flow Yield	-102.27%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$9.20M
Net Income (TTM)	-$19.74M
Free Cash Flow (TTM)	-$16.31M
Net Debt	-$6.75M
Working Capital	$38.78M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-40.16%
Return on Invested Capital	-30.31%